Harvoni ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 254 | ポルフィリン症 | 1 |
254. ポルフィリン症
臨床試験数 : 70 / 薬物数 : 54 - (DrugBank : 19) / 標的遺伝子数 : 19 - 標的パスウェイ数 : 35
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03118674 (ClinicalTrials.gov) | September 6, 2017 | 13/4/2017 | Harvoni Treatment Porphyria Cutanea Tarda | Newer Direct-Acting Anti-Viral Agents as Sole Therapy of Porphyria Cutanea Tarda in Subjects With Chronic Hepatitis C | Porphyria Cutanea Tarda;Hepatitis C | Drug: Harvoni | Wake Forest University Health Sciences | Gilead Sciences;National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);National Institutes of Health (NIH) | Active, not recruiting | 18 Years | N/A | All | 25 | Phase 2 | United States |